Clovis Oncology (NASDAQ:CLVS) – Stock analysts at Leerink Swann issued their Q3 2018 earnings estimates for Clovis Oncology in a research report issued on Monday, September 24th. Leerink Swann analyst A. Berens forecasts that the biopharmaceutical company will post earnings of ($1.52) per share for the quarter. Leerink Swann has a “Market Perform” rating and a $30.00 price target on the stock. Leerink Swann also issued estimates for Clovis Oncology’s Q4 2018 earnings at ($1.51) EPS, FY2018 earnings at ($6.51) EPS, FY2019 earnings at ($4.77) EPS, FY2020 earnings at ($1.50) EPS, FY2021 earnings at $1.10 EPS and FY2022 earnings at $2.65 EPS.

Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.38) by ($0.56). The firm had revenue of $23.76 million for the quarter, compared to the consensus estimate of $22.44 million. Clovis Oncology had a negative return on equity of 94.28% and a negative net margin of 382.83%. The firm’s revenue was up 62.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.29) EPS.

CLVS has been the subject of several other research reports. ValuEngine upgraded shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 2nd. Guggenheim assumed coverage on shares of Clovis Oncology in a research report on Monday, September 17th. They set a “buy” rating for the company. Gabelli restated a “buy” rating on shares of Clovis Oncology in a research report on Monday, July 16th. JPMorgan Chase & Co. restated a “buy” rating and set a $71.00 price target on shares of Clovis Oncology in a research report on Friday, September 21st. Finally, Zacks Investment Research downgraded shares of Clovis Oncology from a “hold” rating to a “sell” rating in a report on Tuesday, July 10th. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $73.41.

Clovis Oncology stock opened at $29.69 on Thursday. The stock has a market cap of $1.65 billion, a PE ratio of -5.80 and a beta of 1.01. The company has a debt-to-equity ratio of 1.84, a current ratio of 10.03 and a quick ratio of 9.21. Clovis Oncology has a one year low of $29.52 and a one year high of $86.26.

Hedge funds have recently bought and sold shares of the stock. Ladenburg Thalmann Financial Services Inc. lifted its holdings in Clovis Oncology by 5,000.0% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,550 shares of the biopharmaceutical company’s stock worth $135,000 after purchasing an additional 2,500 shares during the period. Quantbot Technologies LP acquired a new stake in Clovis Oncology in the first quarter worth about $146,000. Advisors Asset Management Inc. lifted its holdings in Clovis Oncology by 1,017.5% in the second quarter. Advisors Asset Management Inc. now owns 56,668 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 51,597 shares during the period. Summit Trail Advisors LLC lifted its holdings in Clovis Oncology by 4,092.7% in the first quarter. Summit Trail Advisors LLC now owns 249,258 shares of the biopharmaceutical company’s stock worth $249,000 after purchasing an additional 243,313 shares during the period. Finally, LPL Financial LLC lifted its holdings in Clovis Oncology by 66.6% in the first quarter. LPL Financial LLC now owns 5,461 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 2,184 shares during the period.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Recommended Story: Hedge Funds

Earnings History and Estimates for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.